- Showcasing end-to-end manufacturing capabilities from pDNA to drug substance and drug product

PCMO (Pilot Center for Microbia Process Optimization) participated in BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), showcasing its biopharmaceutical development and manufacturing infrastructure and CDMO services while expanding its collaborative network with key organizations in Korea's biotechnology industry.

From October 28 to 30, PCMO operated an exhibition booth at BIX 2026, held at COEX in Seoul. Marking its fifth consecutive year of operating an independent booth, PCMO welcomed approximately 120 visitors and held meetings with seven organizations to explore potential collaboration opportunities in biopharmaceutical development and manufacturing.

At the exhibition, PCMO placed a particular focus on its recently established mRNA manufacturing facility, highlighting its manufacturing infrastructure and capabilities to support the development of next-generation vaccines and therapeutics. The center introduced its key services, including process development (CDO), cell bank manufacturing, drug substance and drug product manufacturing (CMO), quality control testing and storage, and GMP consulting. Through these services, PCMO demonstrated its ability to support biopharmaceutical companies throughout the development and manufacturing process, from process development to manufacturing and quality control, tailored to their respective development stages and needs.

With the establishment of its mRNA manufacturing facility, PCMO has expanded its capabilities beyond microbial-based biopharmaceutical manufacturing to include support for mRNA drug development and production. In particular, PCMO has established an integrated manufacturing infrastructure that enables processes ranging from pDNA manufacturing, mRNA synthesis, and delivery system manufacturing to drug substance and drug product manufacturing.

These capabilities are expected to enable PCMO to support the production of clinical trial materials and process validation for biopharmaceutical companies, providing an integrated support system from early-stage development through GMP-based manufacturing. By reducing the burden of establishing manufacturing infrastructure and improving the efficiency of process development and validation, PCMO aims to contribute to shortening biopharmaceutical development timelines.

Through its participation in BIX 2026, PCMO plans to continue strengthening its CDMO capabilities to address the evolving needs of biopharmaceutical companies and contribute to the advancement of technological development and the expansion of the business ecosystem in Korea's biotechnology industry.